Install
Master the Science of Success through aspirational coverage for executive-level decisions, leadership, management, strategy and commercialization professionals.
- 69articles · 30d
- 1+ day agolatest article
- Aug 18, 2026earliest in window
- 94%with images
- 224avg words
- Business & Industrial 47
- Medical 40
- Economy, Business & Finance 32
- Health 20
- Health & Wellness 20
- Finance & Business 19
- Science & Technology 15
- Science & Nature 5
Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
Zeno???s Paradox, Orphan Product Access and the Future of Unmet Need
3+ day, 7+ hour ago (364+ words) Unmet need is likely a new battlefield impacting prior authorization. CMS ACCESS Model: Changing the Landscape of Disease Management Orphan Product Risk Contracting Future Phase III Trial Planning: Payer Point of View Zeno’s paradox is a riddle about motion and…...
The Agentic AI Revolution in Biopharma
3+ day, 8+ hour ago (1556+ words) How agentic artificial intelligence is transforming the value chain from discovery to commercialization. The biopharmaceutical industry is undergoing a profound transformation, driven by the emergence of agentic artificial intelligence (AI). Unlike traditional AI models that require continuous human guidance, agentic…...
Practical Testing Methods for High Cortisol Levels
3+ day, 13+ hour ago (187+ words) Dr. Elena Christofides on why the overnight dexamethasone suppression test is the only cortisol screen that actually identifies HPA dysfunction. GLP-1 medications might be most well-known as weight-loss options, but they were originally developed as a treatment for type 2 diabetes....
How Life Sciences Companies Can Create Real Impact With Patient Engagement
3+ day, 13+ hour ago (165+ words) A “maturity curve” can help organizations move engagement beyond performative gestures to a strategic asset. For more than 20 years now, companies in the life sciences industry have waved the banner of patient-centricity, spending on advisory boards, listening sessions and even…...
Artisan Partners??? Director Calls for Novartis Board Shake-Up
3+ day, 14+ hour ago (362+ words) Artisan Partners' David Samra is publicly calling for Novartis to overhaul its board and compensation structure following back-to-back trial failures. A major shareholder in Novartis calls for a shake-up of the Swiss drugmaker's board to improve corporate governance, after the…...
HHS Confirms Four Senior FDA Leaders, Including Agency's First-Ever AI Deputy Commissioner
4+ day, 15+ hour ago (449+ words) Pharmaceutical Executive...
Kura Oncology Spins Out Caspian Therapeutics With $50 Million to Test Menin Inhibition as a Disease-Modifying Approach to Diabetes
4+ day, 15+ hour ago (200+ words) Kura Oncology spins out Caspian Therapeutics to apply its menin inhibitor expertise to diabetes — with Eli Lilly validating the science. The financing is designed to fund KO-7246 — a next-generation, highly selective oral menin inhibitor purpose-built for chronic metabolic disease — through…...
IBD's Most Persistent Gap: Q&A with Christian Thienel
4+ day, 20+ hour ago (394+ words) Back Bay’s director discusses why IBD remains underserved — JAK inhibitor constraints, emerging oral mechanisms, and the durability gap. In 2024, Pharmaceutical Executive reported on a survey that showed a significant number of patients suffering from irritable bowel disease (IBD) struggle to…...
Unlocking the Future of Real-World Data & Research | PharmExec
4+ day, 20+ hour ago (40+ words) Unlocking the Future of Real-World Data & Research Pharmaceutical Executive Pharmaceutical Executive Daily: Moonwalk Biosciences' $70 Million Series B Trusted Research Environments Are Reshaping Real-World Data Access: Q&A with Mark Cziraky FDA Approves Zanvastro for Alexander Disease in Pediatrics & Adults...
How Elevated Cortisol Levels Can Impact Type II Diabetes Treatments
4+ day, 20+ hour ago (218+ words) Dr. Elena Christofides on why cortisol dysregulation may explain why so many patients fail to respond to GLP-1 and incretin therapies. GLP-1 medications might be most well-known as weight-loss options, but they were originally developed as a treatment for type…...